The European Medicines Agency is expected to uphold its previous recommendation against EU marketing approval for MaaT Pharma’s investigational microbiota-based therapy for acute graft-versus-host disease.
The European Medicines Agency is expected to uphold its previous recommendation against EU marketing approval for MaaT Pharma’s investigational microbiota-based therapy for acute graft-versus-host disease.